Leukemia clinical trials in Idaho

10 actively recruiting leukemia trials at 10 sites across Idaho.

Data from ClinicalTrials.gov · last refreshed 2026-10-01

Phase 3 Recruiting NIH

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT04269902

Sites in Idaho:

Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
Saint Luke's Cancer Institute - Boise — Boise, Idaho
Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
Walter Knox Memorial Hospital — Emmett, Idaho

View on ClinicalTrials.gov →

Phase 3 Recruiting Academic/Other

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monocl…

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT03150693

Sites in Idaho:

Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
Saint Luke's Cancer Institute - Boise — Boise, Idaho
Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
Walter Knox Memorial Hospital — Emmett, Idaho

View on ClinicalTrials.gov →

Phase 3 Recruiting Academic/Other

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in …

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT07321652

Sites in Idaho:

Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
Idaho Urologic Institute-Meridian — Meridian, Idaho
Saint Alphonsus Cancer Care Center-Nampa — Nampa, Idaho

View on ClinicalTrials.gov →

Phase 3 Recruiting Network

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…

Sponsor: Children's Oncology Group

NCT ID: NCT03959085

Sites in Idaho:

Saint Luke's Cancer Institute - Boise — Boise, Idaho

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myelo…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT05564390

Sites in Idaho:

Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
Saint Luke's Cancer Institute - Boise — Boise, Idaho
Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
Saint Luke's Cancer Institute - Fruitland — Fruitland, Idaho

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back after a period…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT03739814

Sites in Idaho:

Saint Luke's Cancer Institute - Boise — Boise, Idaho
Saint Luke's Cancer Institute - Fruitland — Fruitland, Idaho
Saint Luke's Cancer Institute - Meridian — Meridian, Idaho
Saint Alphonsus Cancer Care Center-Nampa — Nampa, Idaho
Saint Luke's Cancer Institute - Nampa — Nampa, Idaho

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT04546399

Sites in Idaho:

Saint Luke's Cancer Institute - Boise — Boise, Idaho

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT05554393

Sites in Idaho:

Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
Saint Luke's Cancer Institute - Boise — Boise, Idaho
Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
Saint Luke's Cancer Institute - Fruitland — Fruitland, Idaho

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial studies how well ASTX727 and venetoclax plus enasidenib works compared to ASTX727 and venetoclax alone for the treatment of older patients with newly diagnosed acute myeloid leukemia (AML) or younge…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT06672146

Sites in Idaho:

Saint Luke's Cancer Institute - Boise — Boise, Idaho
Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
Saint Luke's Cancer Institute - Fruitland — Fruitland, Idaho
Saint Luke's Cancer Institute - Meridian — Meridian, Idaho
Saint Alphonsus Cancer Care Center-Nampa — Nampa, Idaho

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial compares ASTX727 with standard duration versus shorter duration of venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML). ASTX727 is a combination of decitabine and cedazuridi…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT07437950

Sites in Idaho:

Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
Kootenai Clinic Cancer Services - Post Falls — Post Falls, Idaho
Kootenai Clinic Cancer Services - Sandpoint — Sandpoint, Idaho

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-01